Literature DB >> 24867991

Antagonism between bacteriostatic and bactericidal antibiotics is prevalent.

Paolo S Ocampo1, Viktória Lázár2, Balázs Papp2, Markus Arnoldini3, Pia Abel zur Wiesch4, Róbert Busa-Fekete5, Gergely Fekete2, Csaba Pál2, Martin Ackermann3, Sebastian Bonhoeffer6.   

Abstract

Combination therapy is rarely used to counter the evolution of resistance in bacterial infections. Expansion of the use of combination therapy requires knowledge of how drugs interact at inhibitory concentrations. More than 50 years ago, it was noted that, if bactericidal drugs are most potent with actively dividing cells, then the inhibition of growth induced by a bacteriostatic drug should result in an overall reduction of efficacy when the drug is used in combination with a bactericidal drug. Our goal here was to investigate this hypothesis systematically. We first constructed time-kill curves using five different antibiotics at clinically relevant concentrations, and we observed antagonism between bactericidal and bacteriostatic drugs. We extended our investigation by performing a screen of pairwise combinations of 21 different antibiotics at subinhibitory concentrations, and we found that strong antagonistic interactions were enriched significantly among combinations of bacteriostatic and bactericidal drugs. Finally, since our hypothesis relies on phenotypic effects produced by different drug classes, we recreated these experiments in a microfluidic device and performed time-lapse microscopy to directly observe and quantify the growth and division of individual cells with controlled antibiotic concentrations. While our single-cell observations supported the antagonism between bacteriostatic and bactericidal drugs, they revealed an unexpected variety of cellular responses to antagonistic drug combinations, suggesting that multiple mechanisms underlie the interactions.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24867991      PMCID: PMC4135978          DOI: 10.1128/AAC.02463-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo.

Authors:  H K Johansen; T G Jensen; R B Dessau; B Lundgren; N Frimodt-Moller
Journal:  J Antimicrob Chemother       Date:  2000-12       Impact factor: 5.790

2.  Is chloramphenicol making a comeback?

Authors:  Orna Nitzan; Uri Suponitzky; Yoram Kennes; Bibiana Chazan; Raz Raul; Raul Colodner
Journal:  Isr Med Assoc J       Date:  2010-06       Impact factor: 0.892

3.  Robust growth of Escherichia coli.

Authors:  Ping Wang; Lydia Robert; James Pelletier; Wei Lien Dang; Francois Taddei; Andrew Wright; Suckjoon Jun
Journal:  Curr Biol       Date:  2010-05-27       Impact factor: 10.834

4.  Automated screening in environmental arrays allows analysis of quantitative phenotypic profiles in Saccharomyces cerevisiae.

Authors:  Jonas Warringer; Anders Blomberg
Journal:  Yeast       Date:  2003-01-15       Impact factor: 3.239

5.  Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir.

Authors:  G L Drusano; D Z D'Argenio; S L Preston; C Barone; W Symonds; S LaFon; M Rogers; W Prince; A Bye; J A Bilello
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

6.  Distinct single-cell morphological dynamics under beta-lactam antibiotics.

Authors:  Zhizhong Yao; Daniel Kahne; Roy Kishony
Journal:  Mol Cell       Date:  2012-10-25       Impact factor: 17.970

7.  Metabolite-enabled eradication of bacterial persisters by aminoglycosides.

Authors:  Kyle R Allison; Mark P Brynildsen; James J Collins
Journal:  Nature       Date:  2011-05-12       Impact factor: 49.962

8.  Systematic exploration of synergistic drug pairs.

Authors:  Murat Cokol; Hon Nian Chua; Murat Tasan; Beste Mutlu; Zohar B Weinstein; Yo Suzuki; Mehmet E Nergiz; Michael Costanzo; Anastasia Baryshnikova; Guri Giaever; Corey Nislow; Chad L Myers; Brenda J Andrews; Charles Boone; Frederick P Roth
Journal:  Mol Syst Biol       Date:  2011-11-08       Impact factor: 11.429

9.  The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulations.

Authors:  Peter Ankomah; Paul J T Johnson; Bruce R Levin
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

10.  Bacterial evolution of antibiotic hypersensitivity.

Authors:  Viktória Lázár; Gajinder Pal Singh; Réka Spohn; István Nagy; Balázs Horváth; Mónika Hrtyan; Róbert Busa-Fekete; Balázs Bogos; Orsolya Méhi; Bálint Csörgő; György Pósfai; Gergely Fekete; Balázs Szappanos; Balázs Kégl; Balázs Papp; Csaba Pál
Journal:  Mol Syst Biol       Date:  2013-10-29       Impact factor: 11.429

View more
  71 in total

1.  Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  Brian J Werth
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

2.  Slow growth determines nonheritable antibiotic resistance in Salmonella enterica.

Authors:  Mauricio H Pontes; Eduardo A Groisman
Journal:  Sci Signal       Date:  2019-07-30       Impact factor: 8.192

3.  Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance.

Authors:  Stefany Moreno-Gamez; Alison L Hill; Daniel I S Rosenbloom; Dmitri A Petrov; Martin A Nowak; Pleuni S Pennings
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

4.  Antibacterial, Anticancer and Neuroprotective Activities of Rare Actinobacteria from Mangrove Forest Soils.

Authors:  Adzzie-Shazleen Azman; Iekhsan Othman; Chee-Mun Fang; Kok-Gan Chan; Bey-Hing Goh; Learn-Han Lee
Journal:  Indian J Microbiol       Date:  2016-10-26       Impact factor: 2.461

5.  Classic reaction kinetics can explain complex patterns of antibiotic action.

Authors:  Pia Abel Zur Wiesch; Sören Abel; Spyridon Gkotzis; Paolo Ocampo; Jan Engelstädter; Trevor Hinkley; Carsten Magnus; Matthew K Waldor; Klas Udekwu; Ted Cohen
Journal:  Sci Transl Med       Date:  2015-05-13       Impact factor: 17.956

6.  A data-based mathematical modelling study to quantify the effects of ciprofloxacin and ampicillin on the within-host dynamics of Salmonella enterica during treatment and relapse.

Authors:  Myrto Vlazaki; Omar Rossi; David J Price; Callum McLean; Andrew J Grant; Pietro Mastroeni; Olivier Restif
Journal:  J R Soc Interface       Date:  2020-07-08       Impact factor: 4.118

7.  Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection.

Authors:  Sheng Bi; Xin Yao; Cheng Huang; Xia Zheng; Tianming Xuan; Jifang Sheng; Kaijin Xu; Beiwen Zheng; Qing Yang
Journal:  Infection       Date:  2019-02-07       Impact factor: 3.553

8.  Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugs.

Authors:  Elif Tekin; Casey Beppler; Cynthia White; Zhiyuan Mao; Van M Savage; Pamela J Yeh
Journal:  J R Soc Interface       Date:  2016-06       Impact factor: 4.118

9.  In vitro antagonistic inhibitory effects of palm seed crude oils and their main constituent, lauric acid, with oxacillin in Staphylococcus aureus.

Authors:  Klara Lalouckova; Eva Skrivanova; Johana Rondevaldova; Adela Frankova; Josef Soukup; Ladislav Kokoska
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

Review 10.  Suppressive drug combinations and their potential to combat antibiotic resistance.

Authors:  Nina Singh; Pamela J Yeh
Journal:  J Antibiot (Tokyo)       Date:  2017-09-06       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.